• Recruiting

NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM

NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma


STI-6129

This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.


Sponsor

Sorrento Therapeutics, Inc

 

ClinicalTrials.gov Identifier: NCT05308225

Official Title: A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : April 4, 2022


Click here to see details on ClinicalTrials.gov

 

Biological: STI-6129

 

STI 6129

Anti-CD38 Antibody-drug Conjugate STI-6129 (Code C174057)

ADC STI-6129

Anti-CD38 ADC STI-6129

Anti-CD38 Antibody-drug Conjugate STI-6129

Anti-CD38-Duostatin 5.2 ADC STI-6129

CD38-077

LNDS1001

STI 6129

STI-6129

STI6129

 

Locations

United States, Ohio




Posts Archive